10x Genomics settles patent litigation with Bruker; to receive $68M upfront plus royalties

10x Genomics, Inc.

Settled all patent litigation with Bruker (formerly NanoString) regarding spatial biology platforms; all claims dismissed with prejudice.
10x expects $68M in upfront nonrefundable payments, paid in equal quarterly installments with interest from Q3 2025 to Q2 2026.
Ongoing royalty payments on licensed products and services for the life of the licensed patents.
Litigation began in 2021–2022 targeting NanoString's GeoMx and CosMx spatial platforms; Bruker assumed liabilities in May 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.